Sugi Predict

Sugi Predict / Compounds / SCHEMBL6322764

SCHEMBL6322764

SCHEMBL6322764

Cc1ccc2nc(-c3ccc(N)cc3)[nH]c2c1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 9/20 0.76
▸ NPC1 O15118 8/20 0.76
▸ KDM4E B2RXH2 8/20 0.76
▸ MAPT P10636 8/20 0.76
▸ SMN1; SMN2 Q16637 7/20 0.76
▸ RAB9A P51151 7/20 0.76
▸ MEN1 O00255 6/20 0.76
▸ KMT2A Q03164 6/20 0.76
▸ GFER P55789 5/20 0.76
▸ GAA P10253 5/20 0.76
▸ GLA P06280 4/20 0.76
▸ RXFP1 Q9HBX9 3/20 0.76
▸ RECQL P46063 3/20 0.76
▸ CACNA1B Q00975 1/20 0.73
▸ APBA1 Q02410 1/20 0.73
▸ HPGD P15428 7/20 0.71
▸ POLB P06746 4/20 0.71
▸ HSD17B10 Q99714 4/20 0.71
▸ PKM P14618 3/20 0.71
▸ NFKB1 P19838 2/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13599850 0.92 NPC1 (0.81) ALDH1A1NPC1KDM4EMAPTSMN1; SMN2
SCHEMBL13183701 0.90 NPC1 (0.78) ALDH1A1NPC1KDM4EMAPTSMN1; SMN2
SCHEMBL15496393 0.87 NPC1 (0.66) ALDH1A1NPC1KDM4EMAPTSMN1; SMN2
SCHEMBL2245390 0.87 ALDH1A1 (0.61) ALDH1A1NPC1KDM4EMAPTSMN1; SMN2
SCHEMBL363703 0.86 MEN1 (1.00) ALDH1A1NPC1KDM4EMAPTSMN1; SMN2
SCHEMBL15443953 0.86 MEN1 (0.87) ALDH1A1NPC1KDM4EMAPTSMN1; SMN2
Barbituric Acid SCHEMBL11054933 0.86 ALDH1A1 (0.57) ALDH1A1NPC1KDM4EMAPTSMN1; SMN2
SCHEMBL21096315 0.86 NT5E (0.86) ALDH1A1NPC1KDM4EMAPTSMN1; SMN2
SCHEMBL6124301 0.85 NPC1 (0.71) ALDH1A1NPC1KDM4EMAPTSMN1; SMN2
SCHEMBL20677813 0.84 NPC1 (0.75) ALDH1A1NPC1KDM4EMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111875545-A Directional synthesis method and application of 6-substituted benzimidazole derivative 安阳师范学院 2020-11-03 — — CN disclosed
US-20050277686-A1 Benzimidazole compounds for regulating IgE SIRCAR JAGADISH C 2005-12-15 — — US disclosed
EP-1555020-A2 Benzimidazole derivatives as modulators IgE Avanir Pharmaceuticals (US) 2005-07-20 — — EP disclosed
US-6919366-B2 Benzimidazole derivatives as modulators of IgE AVANIR PHARMACEUTICALS (US) 2005-07-19 — — US disclosed
US-6911462-B2 Benzimidazole compounds for regulating IgE AVANIR PHARMACEUTICALS (US) 2005-06-28 — — US disclosed
US-20050090504-A1 Piperidinyl and piperazinyl compounds substituted with bicyclo-heterocyclylalkyl groups useful as CCR3 receptor antagonists ROCHE PALO ALTO LLC 2005-04-28 — — US disclosed
US-20050075343-A1 Benzimidazole derivatives as modulators of IgE SIRCAR JAGADISH C (US) 2005-04-07 — — US disclosed
EP-1077700-B1 BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF IgE AVANIR PHARMACEUTICALS (US) 2005-04-06 — — EP disclosed
US-20030100582-A1 Benzimidazole compounds for regulating IgE AVANIR PHARMACEUTICALS 2003-05-29 — — US disclosed
US-20030004203-A1 Benzimidazole derivatives as modulators of IgE AVANIR PHARMACEUTICALS 2003-01-02 — — US disclosed
EP-1077700-A1 BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF IgE Avanir Pharmaceuticals (US) 2001-02-28 — — EP disclosed
WO-1999061020-A1 BENZIMIDAZOLE ANALOGS AS DOWN-REGULATORS OF IgE AVANIR PHARMACEUTICALS (US) 1999-12-02 — — WO disclosed
WO-1999061019-A1 BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF IgE AVANIR PHARMACEUTICALS (US) 1999-12-02 — — WO disclosed
US-5468848-A Disazo dyes for yellow dyes for paper and cellulose BAYER AKTIENGESELLSCHAFT (DE) 1995-11-21 — — US disclosed
EP-0632104-A1 Basic azodyes BAYER AG (DE) 1995-01-04 — — EP disclosed
EP-0312838-B1 BASIC AZODYES, THEIR PREPARATION AND THEIR USE BAYER AG (DE) 1993-09-29 — — EP disclosed
US-4920208-A YELLOW MONO-AND DISAZO DYES CONTAINING (4-OXY, 6-OXY-OR -THIOCARBONYL-PYRIMIDIN-2-YL)-AMINO GROUPS; COLORFASTNESS; FIBERS; AFFINITY FOR PAPER SURFACE BAYER AKTIENGESELLSCHAFT (DE) 1990-04-24 — — US disclosed
EP-0312838-A2 Basic azodyes, their preparation and their use BAYER AG (DE) 1989-04-26 — — EP disclosed
EP-0034725-B1 DYESTUFFS CONTAINING IMIDAZOLYLETHYLENE GROUPS AND THEIR USE BASF Aktiengesellschaft (DE) 1984-07-25 — — EP disclosed
EP-0034725-A2 Dyestuffs containing imidazolylethylene groups and their use BASF Aktiengesellschaft (DE) 1981-09-02 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030100582-A1 Benzimidazole compounds for regulating IgE FCER2, SERPINB1, BRPF3 ALDH1A1 1209/4885NPC1 3329/4885KDM4E 113/4885
US-20050277686-A1 Benzimidazole compounds for regulating IgE FCER2, SERPINB1, BRPF3 ALDH1A1 1209/4885NPC1 3329/4885KDM4E 113/4885
US-20030004203-A1 Benzimidazole derivatives as modulators of IgE IGF1R, IGFBP1, IGFBP4 ALDH1A1 925/4885NPC1 4542/4885KDM4E 578/4885
US-20050090504-A1 Piperidinyl and piperazinyl compounds substituted with bicyclo-heterocyclylalkyl groups useful as CCR3 receptor antagonists CCR9, CCR3, CCR1 ALDH1A1 2336/4885NPC1 2409/4885KDM4E 1973/4885
US-20050075343-A1 Benzimidazole derivatives as modulators of IgE FCER2, HRH4, DBI ALDH1A1 771/4885NPC1 3839/4885KDM4E 278/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.